Condition: Cancer · Sponsor: Tizona Therapeutics, Inc
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
This description comes directly from the study's public registry record.
Tizona Therapeutics, Inc. · 888-585-2990 · clinicaltrials@tizonatx.com
Always discuss trial participation with your own doctor first.
| Arizona Oncology Associates | Tucson, Arizona, United States | Completed |
| University of Southern California | Los Angeles, California, United States | Completed |
| Hoag Memorial Hospital | Newport Beach, California, United States | Completed |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Completed |
| Christiana Care Helen F. Graham Cancer Center | Newark, Delaware, United States | Completed |
| John Hopkins Kimmer Cancer Center | Washington D.C., District of Columbia, United States | Completed |
| Florida Cancer Specialists | Daytona Beach, Florida, United States | Recruiting |
| Florida Cancer Specialists | Fleming Island, Florida, United States | Completed |
| Ocala Oncology Center | Ocala, Florida, United States | Recruiting |
| AdventHealth Research Institute | Orlando, Florida, United States | Completed |
| Illinois Cancer Specialists | Arlington Heights, Illinois, United States | Completed |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04485013